Pyridine → 3,3-dimethyl-N-((5-((6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)carbamoyl)cyclobutanecarboxamide
反応式
[CH3:1][C:2]1([CH3:9])[CH2:5][CH:4]([C:6]([NH2:8])=[O:7])[CH2:3]1.C(Cl)(=O)[C:11](Cl)=[O:12].[CH3:16][N:17]1[CH:21]=[C:20]([C:22]2[N:27]=[CH:26][N:25]=[C:24]([O:28][C:29]3[CH:30]=[CH:31][C:32]([NH2:35])=[N:33][CH:34]=3)[CH:23]=2)[CH:19]=[N:18]1.N1C=CC=CC=1>O1CCOCC1.C(Cl)Cl>[CH3:1][C:2]1([CH3:9])[CH2:5][CH:4]([C:6]([NH:8][C:11](=[O:12])[NH:35][C:32]2[CH:31]=[CH:30][C:29]([O:28][C:24]3[CH:23]=[C:22]([C:20]4[CH:19]=[N:18][N:17]([CH3:16])[CH:21]=4)[N:27]=[CH:26][N:25]=3)=[CH:34][N:33]=2)=[O:7])[CH2:3]1参加物
反応物 4
生成物 1
試薬・触媒・溶媒 2
反応条件
- 温度
- 100 °C
実験手順
A solution of Example B1 (0.120 g, 0.944 mmol) in dioxane (10 mL) was treated with oxalyl chloride (0.120 g, 0.945 mmol), heated at 100° C. for 3 h, concentrated to dryness, dissolved in DCM (10 mL), added to a solution of 5-((6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-amine (0.120 g, 0.447 mmol) in DCM (10 mL) and pyridine (0.070 g, 0.885 mmol) and stirred at RT overnight. The mixture was concentrated to dryness treated with MeCN and the solid collected via filtration and dried to afford 3,3-dimethyl-N-((5-((6-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-yl)oxy)pyridin-2-yl)carbamoyl)cyclobutanecarboxamide (95 mg, 49%) as an off-white solid. 1H NMR (400 MHz, DMSO-d6): δ 11.07 (s, 1H), 10.71 (s, 1H), 8.63 (s, 1H), 8.47 (s, 1H), 8.26 (d, J=2.8 Hz, 1H), 8.16 (s, 1H), 8.05 (d, J=9.0 Hz, 1H), 7.75 (dd, J=9.0, 2.8 Hz, 1H), 7.43 (s, 1H), 3.89 (s, 3H), 3.30 (m, 1H), 2.00 (m, 4H), 1.13 (s, 3H), 1.05 (s, 3H); MS (ESI) m/z: 422.2 (M+H+).
後処理
- concentrationconcentrated to dryness
- dissolutiondissolved in DCM (10 mL)
- concentrationThe mixture was concentrated to dryness
- additiontreated with MeCN
- filtrationthe solid collected via filtration
- customdried
出典と根拠
- ORDレコード
- ord-8896553c864b4b9aae904c820f4b0092
- 出典データセット
- uspto-grants-2016_07
- 特許番号
- US09382228B2
反応ノート
読み込み中…